{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:16:40Z","timestamp":1781842600816,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejim.2021.04.009","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T20:36:31Z","timestamp":1619901391000},"page":"77-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Inhaled antibiotics for treatment of adults with non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"90","author":[{"given":"Sofia","family":"Tejada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Campogiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candela","family":"Sol\u00e9-Lleonart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1223-1186","authenticated-orcid":false,"given":"Aroa","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monserrat","family":"Vendrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan B.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejim.2021.04.009_bib0001","first-page":"875","volume":"4","author":"Soyza","year":"2016","journal-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2021.04.009_bib0002","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thx.2010.136119","article-title":"British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.ejim.2021.04.009_bib0003","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17476348.2018.1503540","article-title":"Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis\u2013experiences from recent clinical trials","volume":"12","author":"Paredes Aller","year":"2018","journal-title":"Expert Rev Respir Med"},{"issue":"11","key":"10.1016\/j.ejim.2021.04.009_bib0004","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1157\/13128330","article-title":"Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery","volume":"44","author":"Vendrell","year":"2008","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.ejim.2021.04.009_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2016.05.001","article-title":"Non CF-bronchiectasis: Aetiologic approach, clinical, radiological, microbiological and functional profile in 277 patients","volume":"116","author":"Dimakou","year":"2016","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.ejim.2021.04.009_bib0006","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.rmed.2014.07.021","article-title":"Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance","volume":"109","author":"McDonnell","year":"2015","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ejim.2021.04.009_bib0007","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.chest.2016.10.055","article-title":"Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry","volume":"151","author":"Aksamit","year":"2017","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ejim.2021.04.009_bib0008","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.ejim.2021.04.009_bib0009","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.arbres.2017.07.016","article-title":"Spanish Guidelines on Treatment of Bronchiectasis in Adults","volume":"54","author":"Mart\u00ednez-Garc\u00eda","year":"2018","journal-title":"Arch Bronconeumol"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2021.04.009_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British Thoracic Society Guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.ejim.2021.04.009_bib0011","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.ejim.2021.04.009_bib0012","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.clinthera.2016.08.014","article-title":"Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis","volume":"38","author":"Elborn","year":"2016","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.ejim.2021.04.009_bib0013","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/jamp.2017.1415","article-title":"The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis","volume":"31","author":"Dhand","year":"2018","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"5","key":"10.1016\/j.ejim.2021.04.009_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051062","article-title":"Inhaled Antibiotic Therapy in Chronic Respiratory Diseases","volume":"18","author":"Maselli","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.ejim.2021.04.009_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.ejim.2021.04.009_bib0016","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00051-2017","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research","volume":"49","author":"Hill","year":"2017","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ejim.2021.04.009_bib0017","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cmi.2019.07.010","article-title":"How does Pseudomonas aeruginosa affect the progression of bronchiectasis?","volume":"26","author":"Chai","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.ejim.2021.04.009_bib0018","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1469-0691.2005.01217.x","article-title":"Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients","volume":"11","author":"Cant\u00f3n","year":"2005","journal-title":"Clin Microbiol Infect"},{"issue":"4 Pt 1","key":"10.1016\/j.ejim.2021.04.009_bib0019","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1164\/ajrccm.162.4.9906120","article-title":"An investigation into causative factors in patients with bronchiectasis","volume":"162","author":"Pasteur","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.ejim.2021.04.009_bib0020","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis","volume":"7","author":"Laska","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ejim.2021.04.009_bib0021","first-page":"343:d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"18","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2021.04.009_bib0022","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejim.2021.04.009_bib0023","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.ejim.2021.04.009_bib0024","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ejim.2021.04.009_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ejim.2021.04.009_bib0026","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ejim.2021.04.009_bib0027","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ejim.2021.04.009_bib0028","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ejim.2021.04.009_bib0029","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.ejim.2021.04.009_bib0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1345\/aph.1E099","article-title":"Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa","volume":"39","author":"Drobnic","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.ejim.2021.04.009_bib0031","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000486134","article-title":"A Prospective Trial of Nebulized Amikacin in the Treatment of Bronchiectasis Exacerbation","volume":"95","author":"Ailiyaer","year":"2018","journal-title":"Respiration"},{"issue":"8","key":"10.1016\/j.ejim.2021.04.009_bib0032","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"189","author":"Haworth","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ejim.2021.04.009_bib0033","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2021.04.009_bib0034","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2147\/COPD.S209513","article-title":"Nebulized Colistin And Continuous Cyclic Azithromycin In Severe COPD Patients With Chronic Bronchial Infection Due To Pseudomonas aeruginosa: A Retrospective Cohort Study","volume":"14","author":"Mont\u00f3n","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"10.1016\/j.ejim.2021.04.009_bib0035","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.chest.2018.01.044","article-title":"Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment","volume":"153","author":"Pomares","year":"2018","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.ejim.2021.04.009_bib0036","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.ejim.2021.04.009_bib0037","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.cmi.2019.04.017","article-title":"Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection","volume":"25","author":"VanDevanter","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.ejim.2021.04.009_bib0038","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ejim.2021.04.009_bib0039","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.01899-2015","article-title":"Clinical phenotypes in adult patients with bronchiectasis","volume":"47","author":"Aliberti","year":"2016","journal-title":"Eur Respir J"},{"issue":"2 Pt 1","key":"10.1016\/j.ejim.2021.04.009_bib0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ejim.2021.04.009_bib0041","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.ejim.2021.04.009_bib0042","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0954-6111(99)90090-2","article-title":"Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa","volume":"93","author":"Orriols","year":"1999","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.ejim.2021.04.009_bib0043","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cmi.2017.04.011","article-title":"Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases","volume":"23","author":"Rello","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.ejim.2021.04.009_bib0044","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1523\/JNEUROSCI.07-11-03378.1987","article-title":"Segregation of form, color, and stereopsis in primate area 18","volume":"7","author":"Hubel","year":"1987","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.ejim.2021.04.009_bib0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5694\/mja14.00287","article-title":"Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines","volume":"202","author":"Chang","year":"2015","journal-title":"Med J Aust"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2021.04.009_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British Thoracic Society Guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.ejim.2021.04.009_bib0047","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/thoraxjnl-2019-213929","article-title":"British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease","volume":"75","author":"Smith","year":"2020","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.ejim.2021.04.009_bib0048","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.arbres.2016.12.003","article-title":"Etiology of Bronchiectasis in a Cohort of 2047 Patients. An Analysis of the Spanish Historical Bronchiectasis Registry","volume":"53","author":"Olveira","year":"2017","journal-title":"Arch Bronconeumol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521001242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521001242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:34:07Z","timestamp":1760607247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620521001242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":48,"alternative-id":["S0953620521001242"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2021.04.009","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled antibiotics for treatment of adults with non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2021.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}